Ipca tumbles on quality concerns at Indian site
This article was originally published in Scrip
Shares of the Indian generics company, Ipca Laboratories, tumbled after it said that it had voluntarily referred certain quality "non-conformances" at its Indore facility to the US FDA.
You may also be interested in...
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.